[go: up one dir, main page]

MA26702A1 - Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation - Google Patents

Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation

Info

Publication number
MA26702A1
MA26702A1 MA25827A MA25827A MA26702A1 MA 26702 A1 MA26702 A1 MA 26702A1 MA 25827 A MA25827 A MA 25827A MA 25827 A MA25827 A MA 25827A MA 26702 A1 MA26702 A1 MA 26702A1
Authority
MA
Morocco
Prior art keywords
migraine
treatment
preparation
pharmaceutical compositions
metoclopramide
Prior art date
Application number
MA25827A
Other languages
English (en)
Inventor
Harry Sands Georges
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26702A1 publication Critical patent/MA26702A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

métoclopramide sont associés dans l'organisme d'un mammifère souffrant de migraine. 15. Procédé pour la production d'une composition pharmaceutique destinée au traitement de la migraine suivant les revendications 12 et 14, caractérisé en ce qu'il comprend l'association d'élétriptan, de métoclopramide et d'un support pharmaceutiquement acceptable. Compositions pharmaceutiques pour le traitement de la migraine, et procédé pour leur préparation La présente invention concerne une composition pharmaceutique comprenant du métoclopramide, un agoniste des récepteurs 5HT1 et un support pharmaceutiquement acceptable. Elle concerne également un procédé pour sa préparation. Application : utilisation de cette composition pharmaceutique pour le traitement de la migraine chez un mammifère.
MA25827A 1998-10-30 1999-10-27 Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation MA26702A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30

Publications (1)

Publication Number Publication Date
MA26702A1 true MA26702A1 (fr) 2004-12-20

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25827A MA26702A1 (fr) 1998-10-30 1999-10-27 Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation

Country Status (34)

Country Link
US (2) US6255334B1 (fr)
EP (1) EP1126840A1 (fr)
JP (1) JP2002528497A (fr)
KR (1) KR20010089363A (fr)
CN (1) CN1325304A (fr)
AP (1) AP2001002129A0 (fr)
AR (1) AR019246A1 (fr)
AU (1) AU5994799A (fr)
BG (1) BG105534A (fr)
BR (1) BR9914901A (fr)
CA (1) CA2348543A1 (fr)
CO (1) CO4950530A1 (fr)
CZ (1) CZ20011468A3 (fr)
EA (1) EA200100284A1 (fr)
EE (1) EE200100243A (fr)
GT (1) GT199900189A (fr)
HK (1) HK1040929A1 (fr)
HR (1) HRP20010298A2 (fr)
HU (1) HUP0104696A3 (fr)
ID (1) ID28291A (fr)
IL (1) IL141957A0 (fr)
IS (1) IS5898A (fr)
MA (1) MA26702A1 (fr)
NO (1) NO20012013D0 (fr)
OA (1) OA11669A (fr)
PA (1) PA8484801A1 (fr)
PE (1) PE20001284A1 (fr)
PL (1) PL347541A1 (fr)
SK (1) SK5522001A3 (fr)
TN (1) TNSN99203A1 (fr)
TR (1) TR200101174T2 (fr)
TW (1) TW524692B (fr)
WO (1) WO2000025778A1 (fr)
ZA (1) ZA200103322B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
CA2446904A1 (fr) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
ATE415155T1 (de) * 2001-05-24 2008-12-15 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
WO2003041693A1 (fr) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Administration de diazepam a travers une voie pulmonaire
WO2003057188A1 (fr) 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivrance de cafeine par voie inhalee
WO2003094900A1 (fr) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Distribution de medicament a base d'amines par voie d'inhalation
EP1567164B1 (fr) 2002-11-26 2009-01-14 Alexza Pharmaceuticals, Inc. Utilisation de loxapine pour la fabrication d'un analgesique
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
WO2004104493A2 (fr) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Procede de regulation thermique uniforme d'un substrat ; unite de chauffage integree et unite d'administration de medicaments recourant a ce procede
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
CA2576961A1 (fr) 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Dispositif de distribution de drogue par aerosol integrant des conditionnements thermiques actionnes par percussion
EP1883451B9 (fr) 2005-04-13 2011-02-09 Neuraxon Inc. Composés indole substitués dépourvus d'activité inhibitrice
WO2007118314A1 (fr) * 2006-04-13 2007-10-25 Neuraxon, Inc. Indoles 1,5- et 3,6-substitués à activité inhibitrice vis-à-vis de nos
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP2121088B1 (fr) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
CA2705835A1 (fr) * 2007-11-16 2009-05-22 Neuraxon, Inc. Composes d'indole et procedes de traitement de la douleur viscerale
CA2705422A1 (fr) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Procedes de traitement de la douleur viscerale
CA2705833A1 (fr) * 2007-11-16 2009-05-22 Subhash C. Annedi Composes d'indole 3,5-substitues ayant une activite d'inhibition de la reabsorption de la nos et de la noradrenaline
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine
WO2019152873A1 (fr) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Dispositif aérosol à condensation électrique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
CO4950530A1 (es) 2000-09-01
TW524692B (en) 2003-03-21
US20010020036A1 (en) 2001-09-06
AR019246A1 (es) 2001-12-26
PA8484801A1 (es) 2000-09-29
US6255334B1 (en) 2001-07-03
IS5898A (is) 2001-03-16
EP1126840A1 (fr) 2001-08-29
NO20012013L (no) 2001-04-24
TNSN99203A1 (fr) 2005-11-10
AP2001002129A0 (en) 2001-06-30
TR200101174T2 (tr) 2001-10-22
OA11669A (en) 2005-01-05
BR9914901A (pt) 2001-07-17
KR20010089363A (ko) 2001-10-06
ID28291A (id) 2001-05-10
JP2002528497A (ja) 2002-09-03
WO2000025778A1 (fr) 2000-05-11
CN1325304A (zh) 2001-12-05
HUP0104696A3 (en) 2003-05-28
CZ20011468A3 (cs) 2002-04-17
HK1040929A1 (zh) 2002-06-28
ZA200103322B (en) 2002-06-10
IL141957A0 (en) 2002-03-10
GT199900189A (es) 2001-04-21
CA2348543A1 (fr) 2000-05-11
NO20012013D0 (no) 2001-04-24
PE20001284A1 (es) 2000-11-22
SK5522001A3 (en) 2002-05-09
HRP20010298A2 (en) 2002-06-30
EE200100243A (et) 2002-12-16
EA200100284A1 (ru) 2001-10-22
PL347541A1 (en) 2002-04-08
BG105534A (en) 2001-12-29
HUP0104696A2 (hu) 2002-05-29
AU5994799A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
MA26702A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
DZ2639A1 (fr) Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
EA200100872A1 (ru) Композиция валдекоксиба
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
EP0738152A4 (fr) Agents de chimioprevention ou de chimiotherapie du cancer du colon a base de derives de l'acide 2-hydroxy-5-phenylazobenzoique
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
NZ509762A (en) 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
MA27590A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
Grootveld et al. BMS-561392. Bristol-Myers Squibb
DZ2948A1 (fr) Dérivé d'indole nouveau, procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA24704A1 (fr) Formulations nouvelles de paroxetine et procede pour leur preparation
GB2266665B (en) 5-HT1-like receptor agonist for rectal administration
EA200400302A1 (ru) Способ лечения первичной бессонницы
DZ2954A1 (fr) Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
TNSN98124A1 (fr) Compositions de sertraline solubilisee
WO2003104253A3 (fr) Estratrienes 9-alpha substitues servant d'oestrogenes selectivement actifs